Emmanuelle Ferrant

2.0k total citations
34 papers, 756 citations indexed

About

Emmanuelle Ferrant is a scholar working on Genetics, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Emmanuelle Ferrant has authored 34 papers receiving a total of 756 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 15 papers in Pathology and Forensic Medicine and 8 papers in Epidemiology. Recurrent topics in Emmanuelle Ferrant's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Antifungal resistance and susceptibility (5 papers). Emmanuelle Ferrant is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Antifungal resistance and susceptibility (5 papers). Emmanuelle Ferrant collaborates with scholars based in France, United States and Italy. Emmanuelle Ferrant's co-authors include Nicolás Isambert, Bruno Coudert, P. Fumoleau, Ingrid Lafon, Denis Caillot, Michel Toubeau, François Brunotte, Frédéric Dalle, Olivier Casasnovas and Alexandre Cochet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Emmanuelle Ferrant

32 papers receiving 749 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emmanuelle Ferrant France 11 277 234 234 232 152 34 756
Damien Roos‐Weil France 14 250 0.9× 138 0.6× 140 0.6× 316 1.4× 251 1.7× 82 896
Liliana Baila Belgium 14 119 0.4× 277 1.2× 238 1.0× 179 0.8× 225 1.5× 23 1.2k
C Poynton United Kingdom 12 227 0.8× 109 0.5× 78 0.3× 138 0.6× 192 1.3× 20 592
Federico Silvestri Italy 13 208 0.8× 133 0.6× 49 0.2× 224 1.0× 169 1.1× 30 632
Koh Izumiyama Japan 13 147 0.5× 207 0.9× 74 0.3× 38 0.2× 124 0.8× 55 609
Keiko Hodohara Japan 16 106 0.4× 145 0.6× 58 0.2× 109 0.5× 228 1.5× 56 871
Marianna Criscuolo Italy 21 144 0.5× 128 0.5× 87 0.4× 233 1.0× 194 1.3× 72 1.0k
Matthieu Mahévas France 14 143 0.5× 67 0.3× 59 0.3× 114 0.5× 51 0.3× 38 810
Therese Vallerskog United States 11 87 0.3× 304 1.3× 258 1.1× 64 0.3× 76 0.5× 14 1.1k
Donna Horncastle United Kingdom 11 74 0.3× 172 0.7× 157 0.7× 61 0.3× 190 1.3× 15 577

Countries citing papers authored by Emmanuelle Ferrant

Since Specialization
Citations

This map shows the geographic impact of Emmanuelle Ferrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuelle Ferrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuelle Ferrant more than expected).

Fields of papers citing papers by Emmanuelle Ferrant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuelle Ferrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuelle Ferrant. The network helps show where Emmanuelle Ferrant may publish in the future.

Co-authorship network of co-authors of Emmanuelle Ferrant

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuelle Ferrant. A scholar is included among the top collaborators of Emmanuelle Ferrant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuelle Ferrant. Emmanuelle Ferrant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferrant, Emmanuelle, Rémy Duléry, David Beauvais, et al.. (2025). Anti‐CD19 CAR T‐cell therapy for patients with Richter transformation: A LYSA study from the DESCAR‐T registry. British Journal of Haematology. 207(3). 1143–1147.
2.
Shadman, Mazyar, Talha Munir, Shuo Ma, et al.. (2025). Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results. Journal of Clinical Oncology. 43(21). 2409–2417. 3 indexed citations
3.
4.
Bourbon, Estelle, Kaddour Chabane, Isabelle Mosnier, et al.. (2023). Next-CLL, a New Next-Generation Sequencing–Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia. Journal of Molecular Diagnostics. 25(5). 274–283. 2 indexed citations
5.
Ysebaert, Loïc, Emmanuelle Ferrant, Anne‐Sophie Michallet, et al.. (2023). Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group. Blood. 142(Supplement 1). 3273–3273. 1 indexed citations
6.
Sharman, Jeff P., Miklós Egyed, Wojciech Jurczak, et al.. (2022). Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.. Journal of Clinical Oncology. 40(16_suppl). 7539–7539. 18 indexed citations
7.
8.
9.
Ghez, David, Caroline Protin, Marine Baron, et al.. (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 131(17). 1955–1959. 205 indexed citations
10.
Caillot, Denis, C. Legouge, Ingrid Lafon, et al.. (2018). Mucormycoses pulmonaires au cours des traitements de leucémies aiguës. Analyse rétrospective d’une série de 25 patients. Revue des Maladies Respiratoires. 35(4). 452–464. 3 indexed citations
11.
Legouge, C., P Pagès, Ingrid Lafon, et al.. (2016). Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre. Clinical Microbiology and Infection. 22(9). 782–787. 21 indexed citations
12.
13.
Kanoun, Salim, Cédric Rossi, Alina Berriolo-Riedinger, et al.. (2014). Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 41(9). 1735–1743. 129 indexed citations
14.
Legouge, C., Denis Caillot, Marie‐Lorraine Chrétien, et al.. (2013). The Reversed Halo Sign: Pathognomonic Pattern of Pulmonary Mucormycosis in Leukemic Patients With Neutropenia?. Clinical Infectious Diseases. 58(5). 672–678. 111 indexed citations
15.
Guiu, Boris, Jean–Pierre Cercueil, Romaric Loffroy, et al.. (2009). Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology. 32(3). 238–244. 9 indexed citations
16.
Dalle, Frédéric, Ingrid Lafon, Coralie L’Ollivier, et al.. (2008). A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia. Haematologica. 93(4). 581–587. 19 indexed citations
17.
Favier, Laure, Nicolás Isambert, Sylvie Zanetta, et al.. (2007). Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. The Breast. 17(1). 36–41. 6 indexed citations
18.
Fumoleau, P., Bruno Coudert, Nicolás Isambert, & Emmanuelle Ferrant. (2007). Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Annals of Oncology. 18. v9–v15. 75 indexed citations
19.
Arnould, Laurent, E. Schmitt, Laurence Duvillard, et al.. (2004). Low urine osmolarity as a determinant of cisplatin‐induced nephrotoxicity. International Journal of Cancer. 111(1). 131–137. 21 indexed citations
20.
Cercueil, Jean–Pierre, Emmanuelle Ferrant, Nicolás Isambert, et al.. (2004). Réponse majeure d’un volumineux carcinome hépatocellulaire à une chimioembolisation par pirarubicine, amiodarone et Lipiodol®. Gastroentérologie Clinique et Biologique. 28(12). 1281–1283. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Damien Roos‐Weil Breakdown of academic impact, for papers by Liliana Baila Breakdown of academic impact, for papers by C Poynton Breakdown of academic impact, for papers by Federico Silvestri Breakdown of academic impact, for papers by Koh Izumiyama Breakdown of academic impact, for papers by Keiko Hodohara Breakdown of academic impact, for papers by Marianna Criscuolo Breakdown of academic impact, for papers by Matthieu Mahévas Breakdown of academic impact, for papers by Therese Vallerskog Breakdown of academic impact, for papers by Donna Horncastle
Rankless by CCL
2026